预约演示
Ipsen joins the ADC club with deal worth up to $900m
引进/卖出抗体药物偶联物并购
Ipsen signed a deal with Sutro Biopharma for ADC development. Credit: HJBC via Shutterstock
Ipsen has joined the slewSutro Biopharmaeveloping antibody-drug conjugates (ADC) with the announcement of a new global licensing agreement with Sutro Biopharma for the development of the latter’s STRO-003.
Ipsen declared that the deal would give it exclusive worldwide rights to develop and commercialise the ROR1-targeting ADC STRO-003. Ipsen is accSutro Biopharmaase I preparations, including investiSTRO-003 new drug application (IND) submissions. The Paris, France-headquartered company will also be responsible for the later clinical development and global commercialisation of STRO-003.
Ipsen the partnership, Sutro Biopharma could receive up to $900m in prospective upfront, development, aROR1-targetingmilesSTRO-003edIpsenents. This is inclusive of $90m in near-term payments in the form of tiered royalties on global sales, and an equity investment, dependent on Ipsen’s successful development and commercialisation strategy.STRO-003
STRO-003 is one of threSutro Biopharmaing developed in Sutro’s clinical pipeline. In June 2023, Sutro announced plans to submit INDs for STRO-003 in 2024 and another ADC, STRO-004, in 2025.Ipsen
Kintara and TuHURA enter merger deal to advance oncology pipeline
ADC development has risen in the pharmaceutical industry in recent years with major companies signing high-value deals to gain assets in the modality. In December 2023, Johnson and Johnson signed a $1.7bn licensing deal to acquire an ADC from the South Korean biotech LegoChem. Similarly, Bristol Myers Squibb spent an exorbitant $8.4bn on an ADC deal with SystImmune in the same month.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。